Overview

Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma (RESOLVE)

Status:
Completed

Trial end date:
2019-04-25

Target enrollment:

Participant gender:

Summary

This is a phase 3 study to evaluate the efficacy of ibrutinib in combination with nab-paclitaxel and gemcitabine for the first line treatment of patients with metastatic pancreatic adenocarcinoma.

Phase:

Phase 3

Details

Lead Sponsor:

Pharmacyclics LLC.

Treatments:

Albumin-Bound Paclitaxel
Gemcitabine
Paclitaxel